VTRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Viatris Inc
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$18.26−0.39 (-2.12%)
Close on Oct 19, 2026
- Market cap
- $21.24B
- P/E (TTM)
- –
- Dividend yield
- 2.63%
Viatris Inc revenue by segment
By business segment
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | $8.75B | $8.68B | $8.55B | $8.45B | $8.49B | $8.69B | $8.96B | $9.15B | $9.25B | $9.28B | $9.28B | $9.34B | 59.4% | +3.1% |
| Greater China | $2.58B | $2.46B | $2.33B | $2.28B | $2.23B | $2.18B | $2.17B | $2.16B | $2.15B | $2.14B | $2.16B | $2.15B | 17.5% | +15.8% |
| Emerging Markets Segment | $2.22B | $2.23B | $2.22B | $2.17B | $2.13B | $2.15B | $2.26B | $2.38B | $2.48B | $2.55B | $2.56B | $2.53B | 15.1% | +4.2% |
| Japan, Australia and New Zealand Segment | $1.18B | $1.19B | $1.20B | $1.23B | $1.27B | $1.31B | $1.35B | $1.39B | $1.38B | $1.40B | $1.43B | $1.45B | 8.0% | -6.5% |
| Operating income | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Developed Markets Segment | – | – | – | – | – | – | – | $3.96B | $4.01B | $4.06B | $4.09B | $4.26B | – |
| Greater China | – | – | – | – | – | – | – | $1.41B | $1.40B | $1.40B | $1.43B | $1.40B | – |
| Emerging Markets Segment | – | – | – | – | – | – | – | $948.80M | $1.01B | $1.06B | $1.09B | $1.09B | – |
| Japan, Australia and New Zealand Segment | – | – | – | – | – | – | – | $426.90M | $449.40M | $479.70M | $522.90M | $557.00M | – |
By product or service
| Revenue | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | TTM Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Brands | $9.53B | $9.40B | $9.18B | $9.00B | $8.93B | $9.01B | $9.20B | $9.44B | $9.61B | $9.69B | $9.80B | $9.71B | 64.7% | +6.8% |
| Generics | $5.16B | $5.12B | $5.07B | $5.07B | $5.14B | $5.27B | $5.49B | $5.57B | $5.59B | $5.63B | $5.59B | $6.79B | 35.0% | +0.5% |
| Lipitor | $1.69B | $1.62B | $1.55B | $1.53B | $1.51B | $1.47B | $1.47B | $1.49B | $1.50B | $1.53B | $1.56B | $1.55B | 11.5% | +12.0% |
| Norvasc | $765.10M | $747.60M | $709.90M | $700.90M | $690.10M | $669.30M | $673.30M | $678.90M | $685.50M | $706.00M | $732.40M | $735.60M | 5.2% | +10.9% |
| Lyrica | $487.50M | $495.00M | $487.00M | $494.20M | $497.60M | $493.80M | $495.40M | $501.80M | $513.60M | $526.40M | $556.50M | $563.00M | 3.3% | -2.0% |
| EpiPen Auto-Injectors | $466.50M | $474.10M | $469.70M | $463.80M | $429.80M | $408.50M | $392.00M | $405.90M | $414.60M | $426.60M | $442.20M | $423.50M | 3.2% | +8.5% |
| Viagra | $417.30M | $404.70M | $408.20M | $392.60M | $387.60M | $393.40M | $395.60M | $399.30M | $409.60M | $414.50M | $428.80M | $433.50M | 2.8% | +7.7% |
| Creon | $386.80M | $380.80M | $365.80M | $357.30M | $348.80M | $335.60M | $328.20M | $318.40M | $311.30M | $307.20M | $304.90M | $301.80M | 2.6% | +10.9% |
| Celebrex | $283.00M | $276.60M | $272.90M | $273.80M | $274.60M | $276.80M | $285.60M | $293.60M | $304.20M | $314.00M | $330.60M | $340.20M | 1.9% | +3.1% |
| Zoloft | $277.60M | $267.30M | $254.90M | $246.30M | $240.10M | $237.90M | $235.70M | $239.50M | $241.60M | $237.20M | $235.70M | $231.20M | 1.9% | +15.6% |
| Yupelri | $275.20M | $271.10M | $266.90M | $262.90M | $253.70M | $241.60M | $238.50M | $232.40M | $228.50M | $229.00M | $220.80M | $216.30M | 1.9% | +8.5% |
| Effexor | $264.00M | $260.40M | $257.70M | $254.10M | $253.20M | $252.80M | $252.90M | $256.40M | $255.60M | $257.70M | $262.90M | $259.10M | 1.8% | +4.3% |
| Xalabrands | $158.60M | $160.50M | $158.40M | $153.50M | $156.10M | $161.00M | $166.40M | $177.50M | $184.20M | $189.00M | $193.20M | $193.40M | 1.1% | +1.6% |
| Amitiza | $156.60M | $158.80M | $158.10M | $156.80M | $154.20M | $149.50M | $149.20M | $149.30M | $148.80M | $153.40M | $157.00M | $158.40M | 1.1% | +1.6% |
| Dymista | $149.50M | $158.10M | $163.60M | $166.30M | $176.00M | $182.60M | $188.00M | $191.70M | $192.30M | $195.00M | $200.00M | $196.80M | 1.0% | -15.1% |
| Xanax | $146.60M | $142.40M | $139.90M | $136.90M | $141.30M | $142.80M | $145.00M | $143.60M | $133.20M | $149.60M | $154.80M | $160.70M | 1.0% | +3.8% |
| Complex GX and Biosimilars | – | – | – | – | – | – | – | – | – | – | – | $697.30M | – | – |
| Influvac | – | – | $194.40M | – | – | – | $178.70M | – | – | – | $192.40M | – | – | – |
By region
From the segment and revenue-disaggregation notes of Viatris's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.